Overview
Mild malformations of cortical development (MCD) encompass a spectrum of brain abnormalities affecting cortical architecture, often with subtle clinical presentations and variable imaging findings. These conditions arise from genetic mutations impacting neurodevelopment 1.Diagnosis
Genetic testing targeting known MCD-related genes (e.g., 132 genes reviewed) is essential for diagnosis 1.
Histopathological examination can provide supportive evidence but correlations are not always clear for all genetic variants 1.
Neuroimaging (MRI) often reveals characteristic but non-specific patterns, aiding in clinical suspicion 1.Management
Specific treatment is often tailored to underlying genetic causes and associated symptoms rather than the MCD itself 1.
Symptomatic management includes addressing neurological deficits, seizures, and developmental delays with targeted interventions 1.
There are no universally recommended first-line pharmacological treatments specific to MCD; therapies are individualized 1.Special Populations
Pediatrics: Early genetic and developmental assessments are crucial for guiding intervention strategies 1.
Comorbidities: Management should consider coexisting conditions like epilepsy, which may require antiepileptic drugs (e.g., valproate, levetiracetam) based on clinical response 1.Key Recommendations
Conduct genetic testing for patients suspected of MCD to identify specific genetic mutations guiding management 1 (Evidence: Strong).
Utilize neuroimaging (MRI) to support clinical diagnosis and monitor disease progression 1 (Evidence: Moderate).
Tailor symptomatic treatment plans based on individual patient needs, including addressing seizures and developmental delays 1 (Evidence: Expert opinion).References
1 Brock S, Cools F, Jansen AC. Neuropathology of genetically defined malformations of cortical development-A systematic literature review. Neuropathology and applied neurobiology 2021. link